Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space. With this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging biomarkers.
From the pioneers of simple imaging solutions, this latest innovation to the Brainomix 360 stroke platform can generate critical information from universally available non-contrast CT scans, alerting clinicians of suspected large vessel occlusions (LVO) and intracranial hemorrhages (ICH), supporting treatment and transfer decisions.
The latest advancement will extend the e-Stroke platform to enable messaging and image-sharing across stroke networks, helping to optimize workflow and facilitate faster treatment
e-Stroke Suite 10.0 provides first-ever clot detection from non-contrast CT scans, a paradigm shift
Brainomix's new e-Stroke Mobile App provides landmark capabilities for stroke networks
The latest software includes the new e-Stroke Cloud Service to facilitate faster sharing of results across a stroke network
e-ASPECTS software supports physicians’ diagnostic skills by delivering fast and consistent stroke diagnosis
The new e-Stroke Suite is the complete decision support software for the assessment of CT and MR scans of ischemic stroke patients
e-CTA provides fast, automated collateral assessments powered by AI and big data
New version of Brainomix’s flagship product, e-ASPECTS, offers exciting new features and improvements
The new software version of Brainomix’s flagship product offers exciting new features and improvements